Location History:
- Ikoma, JP (2017)
- Nara, JP (2021)
Company Filing History:
2 out of 281 
1 out of 5 Years Active: 2017-2021
Title: **The Innovative Contributions of Sae Akao**
Introduction
Sae Akao is a prominent inventor based in Nara, Japan, with a commendable portfolio that includes two significant patents. Her work primarily focuses on innovations in the field of medical science, particularly concerning ocular diseases and biochemical interactions.
Latest Patents
Sae Akao holds two notable patents reflecting her groundbreaking research. The first patent is an **Antibody inhibiting binding of VEGF to NRP1**. This invention aims to provide an antibody that effectively inhibits the interaction between vascular endothelial growth factor (VEGF) and neuropilin-1 (NRP1), which is crucial for various therapeutic applications.
The second patent is a **prophylactic or therapeutic agent for posterior ocular disease** containing a specific compound, tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative, as the active ingredient. This invention represents an advancement in treatments aimed at managing ocular diseases, showcasing her commitment to improving patient care.
Career Highlights
Sae Akao has made significant contributions during her career, specifically through her roles at Santen Pharmaceutical Co., Ltd. and Order-Made Medical Research Inc. Her experience in these companies has enabled her to apply her research to practical advancements in pharmaceuticals and medical treatments.
Collaborations
Throughout her career, Sae Akao has worked with esteemed colleagues, including Yasufumi Murakami and Hiroyuki Satofuka. These collaborations have been instrumental in fostering innovative solutions and enhancing research quality within her field.
Conclusion
Sae Akao's contributions as an inventor reveal her dedication to advancing medical science and improving health outcomes. Her patents not only showcase her inventive spirit but also highlight the potential impact her innovations can have in treating ocular diseases. As she continues her work, the medical community anticipates further groundbreaking advancements that will arise from her expertise and creativity.